Literature DB >> 26212614

Live imaging of endogenous Ca²⁺/calmodulin-dependent protein kinase II in neurons reveals that ischemia-related aggregation does not require kinase activity.

Kelsey Barcomb1, Dayton J Goodell1, Don B Arnold2, K Ulrich Bayer1.   

Abstract

The Ca(2+) /calmodulin-dependent protein kinase II (CaMKII) forms 12meric holoenzymes. These holoenzymes cluster into larger aggregates within neurons under ischemic conditions and in vitro when ischemic conditions are mimicked. This aggregation is thought to be mediated by interaction between the regulatory domain of one kinase subunit with the T-site of another kinase subunit in a different holoenzyme, an interaction that requires stimulation by Ca(2+) /CaM and nucleotide for its induction. This model makes several predictions that were verified here: Aggregation in vitro was reduced by the CaMKII inhibitors tatCN21 and tatCN19o (which block the T-site) as well as by KN93 (which is CaM-competitive). Notably, these and previously tested manipulations that block CaMKII activation all reduced aggregation, suggesting an alternative mechanism that instead requires kinase activity. However, experiments with the nucleotide-competitive broad-spectrum kinase inhibitors staurosporin and H7 showed that this is not the case. In vitro, staurosporine and H7 enabled CaMKII aggregation even in the absence of nucleotide. Within rat hippocampal neurons, an intra-body enabled live monitoring of endogenous CaMKII aggregation. This aggregation was blocked by tatCN21, but not by staurosporine, even though both effectively inhibit CaMKII activity. These results support the mechanistic model for CaMKII aggregation and show that kinase activity is not required. CaMKII aggregation is prevented by inhibiting kinase activity with mutations (red italics; shown previously) or inhibitors (red bold; shown here), indicating requirement of kinase activity. However, we show here that nucleotide-competitive inhibitors (green) allow CaMKII aggregation (including endogenous CaMKII within neurons), demonstrating that kinase activity is not required and supporting the current mechanistic model for CaMKII aggregation.
© 2015 International Society for Neurochemistry.

Entities:  

Keywords:  CaMKII; FingR; aggregation; glutamate; hippocampus; ischemia

Mesh:

Substances:

Year:  2015        PMID: 26212614      PMCID: PMC4636925          DOI: 10.1111/jnc.13263

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  48 in total

1.  Selective translocation of Ca2+/calmodulin protein kinase IIalpha (CaMKIIalpha) to inhibitory synapses.

Authors:  Kurt C Marsden; Adi Shemesh; K Ulrich Bayer; Reed C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-08       Impact factor: 11.205

2.  A mechanism for tunable autoinhibition in the structure of a human Ca2+/calmodulin- dependent kinase II holoenzyme.

Authors:  Luke H Chao; Margaret M Stratton; Il-Hyung Lee; Oren S Rosenberg; Joshua Levitz; Daniel J Mandell; Tanja Kortemme; Jay T Groves; Howard Schulman; John Kuriyan
Journal:  Cell       Date:  2011-09-02       Impact factor: 41.582

3.  Excitotoxic neuroprotection and vulnerability with CaMKII inhibition.

Authors:  Nicole M Ashpole; Andy Hudmon
Journal:  Mol Cell Neurosci       Date:  2011-02-21       Impact factor: 4.314

4.  Nucleotides and phosphorylation bi-directionally modulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) binding to the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B.

Authors:  Heather O'Leary; Wallace H Liu; Jacki M Rorabaugh; Steven J Coultrap; K Ulrich Bayer
Journal:  J Biol Chem       Date:  2011-07-18       Impact factor: 5.157

5.  Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor.

Authors:  Rebekah S Vest; Heather O'Leary; Steven J Coultrap; Mark S Kindy; K Ulrich Bayer
Journal:  J Biol Chem       Date:  2010-04-27       Impact factor: 5.157

Review 6.  CaMKII in cerebral ischemia.

Authors:  Steven J Coultrap; Rebekah S Vest; Nicole M Ashpole; Andy Hudmon; K Ulrich Bayer
Journal:  Acta Pharmacol Sin       Date:  2011-06-20       Impact factor: 6.150

Review 7.  Mechanisms of CaMKII action in long-term potentiation.

Authors:  John Lisman; Ryohei Yasuda; Sridhar Raghavachari
Journal:  Nat Rev Neurosci       Date:  2012-02-15       Impact factor: 34.870

8.  Dynamic control of CaMKII translocation and localization in hippocampal neurons by NMDA receptor stimulation.

Authors:  K Shen; T Meyer
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

Review 9.  The molecular and cellular biology of enhanced cognition.

Authors:  Yong-Seok Lee; Alcino J Silva
Journal:  Nat Rev Neurosci       Date:  2009-02       Impact factor: 34.870

10.  Improving a natural CaMKII inhibitor by random and rational design.

Authors:  Steven J Coultrap; K Ulrich Bayer
Journal:  PLoS One       Date:  2011-10-03       Impact factor: 3.240

View more
  7 in total

1.  DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific.

Authors:  Dayton J Goodell; Vincent Zaegel; Steven J Coultrap; Johannes W Hell; K Ulrich Bayer
Journal:  Cell Rep       Date:  2017-06-13       Impact factor: 9.423

2.  Developmental restoration of LTP deficits in heterozygous CaMKIIα KO mice.

Authors:  Dayton J Goodell; Tim A Benke; K Ulrich Bayer
Journal:  J Neurophysiol       Date:  2016-08-17       Impact factor: 2.714

3.  Simultaneous Live Imaging of Multiple Endogenous Proteins Reveals a Mechanism for Alzheimer's-Related Plasticity Impairment.

Authors:  Sarah G Cook; Dayton J Goodell; Susana Restrepo; Don B Arnold; K Ulrich Bayer
Journal:  Cell Rep       Date:  2019-04-16       Impact factor: 9.423

4.  Genetically encoded intrabodies as high-precision tools to visualize and manipulate neuronal function.

Authors:  James S Trimmer
Journal:  Semin Cell Dev Biol       Date:  2021-11-12       Impact factor: 7.499

5.  Young DAPK1 knockout mice have altered presynaptic function.

Authors:  Dayton J Goodell; Jonathan E Tullis; K Ulrich Bayer
Journal:  J Neurophysiol       Date:  2021-04-21       Impact factor: 2.714

6.  CaMKII binding to GluN2B at S1303 has no role in acute or inflammatory pain.

Authors:  Uche P Maduka; Stephanie R White; Mei-Ling A Joiner; Johannes W Hell; Donna L Hammond
Journal:  Brain Res       Date:  2020-10-14       Impact factor: 3.252

7.  Mechanisms and Role of Dendritic Membrane Trafficking for Long-Term Potentiation.

Authors:  Brian G Hiester; Matthew I Becker; Aaron B Bowen; Samantha L Schwartz; Matthew J Kennedy
Journal:  Front Cell Neurosci       Date:  2018-10-30       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.